The Form 4 filing, an SEC report of insider share activity, lists November 12, 2026, as the transaction date. It was filed on November 16, four days later. The reported seller, Charles F. Wagner Jr., is an officer of Vertex Pharmaceuticals (VRTX).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-12 |
| Date of Latest Transaction | 2026-11-12 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 15,286 |
| Price | $547.87 |
| Total Transaction Value | $8,374,740.82 |
| Insider | |
| Ticker Symbol | VRTX |
| Company | VERTEX PHARMACEUTICALS INC / MA |
| Insider Name | WAGNER CHARLES F JR |
| Insider Title | EVP, CO & FO |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 31,764 |
| Position Size Change | 32.49% |
| Filing | |
| Filing Date | 2026-11-16 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share sale reported under transaction code S. It involved one transaction in Vertex Pharmaceuticals stock. The available details do not identify where the shares were sold.
What was the average price of the transaction?
The reported average price was $547.87 per share for the 15,286 shares sold on November 12, 2026.
How did this transaction affect the insider's holdings?
He sold 15,286 shares and reported 31,764 shares owned after the sale. The shares sold made up 32.49% of his reported shares before the trade.
What's the total transaction value?
The total transaction value was $8,374,740.82 for the one reported sale.
Are there any special circumstances around this transaction?
The transaction information includes a Rule 10b5-1 trading-plan reference, but its scope is unclear. These plans set trading instructions in advance. No footnote text or plan terms were available for this report. The reference alone does not confirm whether a plan covered this specific sale. The plan's start date and trading schedule are unknown.
Source: SEC Form 4 filing.
For research purposes only; not investment advice.